These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 12649145

  • 1. Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP).
    Olsen EH, McCain AS, Merricks EP, Fischer TH, Dillon IM, Raymer RA, Bellinger DA, Fahs SA, Montgomery RR, Keith JC, Schaub RG, Nichols TC.
    Blood; 2003 Jul 15; 102(2):436-41. PubMed ID: 12649145
    [Abstract] [Full Text] [Related]

  • 2. A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease.
    Ragni MV, Jankowitz RC, Chapman HL, Merricks EP, Kloos MT, Dillow AM, Nichols TC.
    Haemophilia; 2008 Sep 15; 14(5):968-77. PubMed ID: 18680527
    [Abstract] [Full Text] [Related]

  • 3. Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A.
    Ragni MV, Novelli EM, Murshed A, Merricks EP, Kloos MT, Nichols TC.
    Thromb Haemost; 2013 Feb 15; 109(2):248-54. PubMed ID: 23238591
    [Abstract] [Full Text] [Related]

  • 4. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
    Cattaneo M, Simoni L, Gringeri A, Mannucci PM.
    Br J Haematol; 1994 Feb 15; 86(2):333-7. PubMed ID: 8199023
    [Abstract] [Full Text] [Related]

  • 5. Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models.
    Denis CV, Kwack K, Saffaripour S, Maganti S, André P, Schaub RG, Wagner DD.
    Blood; 2001 Jan 15; 97(2):465-72. PubMed ID: 11154224
    [Abstract] [Full Text] [Related]

  • 6. The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease.
    Johnstone IB, Crane S.
    Can J Vet Res; 1987 Apr 15; 51(2):189-93. PubMed ID: 3111674
    [Abstract] [Full Text] [Related]

  • 7. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan 15; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 8. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ, Gadisseur A, Vangenegten I, Schroyens W, Berneman Z.
    Acta Haematol; 2009 Jan 15; 121(2-3):119-27. PubMed ID: 19506358
    [Abstract] [Full Text] [Related]

  • 9. Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells.
    Haberichter SL, Merricks EP, Fahs SA, Christopherson PA, Nichols TC, Montgomery RR.
    Blood; 2005 Jan 01; 105(1):145-52. PubMed ID: 15331450
    [Abstract] [Full Text] [Related]

  • 10. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
    López-Fernández MF, Blanco-López MJ, Castiñeira MP, Batlle J.
    Am J Hematol; 1992 May 01; 40(1):20-7. PubMed ID: 1566742
    [Abstract] [Full Text] [Related]

  • 11. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A, Berneman Z, Schroyens W, Michiels JJ.
    Acta Haematol; 2009 May 01; 121(2-3):128-38. PubMed ID: 19506359
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biological effect of desmopressin in eight patients with type 2N ('Normandy') von Willebrand disease. Collaborative Group.
    Mazurier C, Gaucher C, Jorieux S, Goudemand M.
    Br J Haematol; 1994 Dec 01; 88(4):849-54. PubMed ID: 7819109
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy.
    Nishino M, Nishino S, Sugimoto M, Shibata M, Tsuji S, Yoshioka A.
    Int J Hematol; 1996 Aug 01; 64(2):127-34. PubMed ID: 8854570
    [Abstract] [Full Text] [Related]

  • 18. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH, Kappers-Klunne MC, Leebeek FW, Michiels JJ.
    Thromb Haemost; 2008 Sep 01; 100(3):462-8. PubMed ID: 18766263
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Storage of factor VIII variants with impaired von Willebrand factor binding in Weibel-Palade bodies in endothelial cells.
    van den Biggelaar M, Bouwens EA, Voorberg J, Mertens K.
    PLoS One; 2011 Sep 01; 6(8):e24163. PubMed ID: 21909383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.